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Background: The polycystic ovary syndrome (PCOS) is considered the most common endocrine disease during the
woman's reproductive life, with prevalence ranging from 5 to 10 % of women of reproductive age. There is a
paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development
of cardiovascular disease (CVD).
Methods: A cross-sectional study was conducted on 78 women aged 18 to 42 years seen at University Hospital of
Maranhão, with a diagnosis of polycystic ovary syndrome according to the Rotterdam criteria. The following variables
of interest were recorded on a protocol form: sociodemographic and behavioral data, body mass index, waist
circumference, fasting glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and systolic and diastolic blood pressure.
Results: Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher
chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.
Conclusion: The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases
in women with polycystic ovary syndrome.
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Polycystic ovary syndrome (PCOS) is an endocrine dis-
order which is characterized mainly by anovulation and
hyperandrogenism. Clinical manifestations range from
irregular menstrual cycles to the absence of menstruation
associated with variable degrees of overweight and an in-
creased risk of developing cardiovascular diseases, among
others [1, 2]. PCOS is the most frequent gynecological
endocrinopathy, affecting 5 to 10 % of premenopausal
women [3]. In Brazil, Melo et al. [4] reported a prevalence
of PCOS of 13.9 % in AGA women at birth and prevalence
in SGA women at birth (30.2 %).
The criteria currently used for the diagnosis of PCOS
are those established by the Rotterdam consensus [5],
which defines the disease as the presence of two of
the three following criteria: oligomenorrhea and/or* Correspondence: joelmaximenes@yahoo.com.br
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creativecommons.org/publicdomain/zero/1.0/anovulation, clinical and/or biochemical signs of hyperan-
drogenism, and polycystic ovaries on ultrasound (presence
of 12 or more follicles measuring 2 to 9 mm in diameter
or with a total volume > 10 cm3 in at least one ovary). The
diagnosis is confirmed after the exclusion of other condi-
tions that can cause chronic anovulation and androgen
excess.
Cardiovascular disease (CVD) is one of the main pub-
lic health problems, accounting for almost half of deaths
in Europe and North America [6] and for 32 % of deaths
in Brazil [7]. Obesity is a condition seen in 40 to 50 % of
women with PCOS and the intensity of its symptoms is
related to the degree of obesity [8]. Obesity alone contrib-
utes to the physiopathology of PCOS and is frequently as-
sociated with hyperinsulinemia [9], hypertriglyceridemia
and reduced high-density lipoprotein cholesterol (HDL-c)
[10], arterial hypertension, and type 2 diabetes mellitus
[11]. These conditions are characterized by the redistribu-
tion of body fat mass, i.e., excess fat deposition in the ab-
dominal region (androgenic obesity), which is associatedess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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and diabetes mellitus [12, 13].
The body mass index (BMI) is the most commonly
used indicator to assess obesity. This indicator evaluates
generalized obesity, but does not measure body fat dis-
tribution [12, 14]. In addition, BMI is a limited tool for
the differentiation between body fat and lean mass and
for the identification of their anatomical location or func-
tion of different fat deposits [15]. In this respect, a new
index, called the lipid accumulation product (LAP), has
been proposed.
Women with PCOS have been shown to be at an in-
creased risk of developing CVD. This risk is even higher
in the presence of obesity when the chances of an al-
tered LAP are high [16]. Thus, the use of this index may
render the evaluation of CVD risk more feasible, practical
and less costly, especially at primary healthcare services in
Brazil. However, few studies have investigated the applica-
tion of this index to the population attending the Brazilian
primary healthcare service the single health system (SUS).
Other risk markers such as the Framingham Score [17]
and the Reynold Risk Score [18] require a larger num-
ber of variables to assess cardiovascular risk, with a
consequent increase in costs and the need for additional
technologies.
The use of more objective diagnostic procedures at
SUS is of particular importance when considering the in-
crease in the incidence of CVD related morbidity and
mortality observed during the nutrition transition, espe-
cially in women with PCOS. In view of the importance
of the LAP index, the objective of the present study was
to evaluate the association between this indicator and
cardiovascular risk factors in women with PCOS, iden-
tify a cutoff point and compare it with changes in other
cardiovascular markers. Our hypothesis is that LAP may
be uncertain in this syndrome.
Subjects and methods
An analytic cross-sectional study was conducted on 78
women aged 18 to 42 years with a diagnosis of PCOS ac-
cording to the Rotterdam criteria [5]. The patients were
seen at University Hospital (HU) of Maranhão (UFMA),
between September 2010 and February 2012. Patients
who do not contemplate such criteria were not sampled.
The non-probabilistic sampling was employed. All
women were submitted to clinical examination, including
the measurement of body weight, height, and WC. For
WC, the lowest circumference between the last rib and
iliac crest [19] was considered. The reference standards
of the World Health Organization (1997) were used for
the classification of nutritional status based on BMI: grade
III thinness ≤ 16.0 kg/m2; grade II thinness: 16.0 –
16.9 kg/m2; grade I thinness: 17.0 – 18.4 kg/m2; eutrophy:
18.5 – 24.9 kg/m2; overweight: 25.0 – 29.9 kg/m2; grade Iobesity: 30.0 – 34.5 kg/m2; grade II obesity: 35.0 –
39.9 kg/m2, and grade III obesity ≥ 40.0 kg/m2[19].
The LAP index was determined using the following
equation: (WC [cm] - 58) x (TG [mmol/L]). The con-
centration of triglycerides in mmol/L used in the equa-
tion was obtained by multiplying their concentration in
mg/dL by 0.0113 [15]. The following variables of interest
were recorded on a protocol form: sociodemographic
and behavioral data, BMI, WC, fasting glucose, total
cholesterol (TC), triglycerides (TG), low density lipopro-
tein cholesterol (LDL-c), high-density lipoprotein choles-
terol (HDL-c), and systolic (SBP) and diastolic blood
pressure (DBP).
The more rigorous guidelines of the International Dia-
betes Federation (IDF) were used to establish cut off
values of CVD risk, which is defined by the presence of
three or more of the following variables: WC ≥ 80 cm con-
sidering ethnic background (since no specific data for
South American women are available, cutoff values for
European women were used); fasting glucose ≥ 5.6 mmol/L
or a previous diagnosis of diabetes; TG ≥ 1.6 mmol/L or
treatment of dyslipidemia; HDL-c < 1.2 mmol/L or treat-
ment of dyslipidemia; SBP ≥ 130 mmHg or treatment, or
DBP ≥ 85 mmHg. In addition, the Fourth Brazilian Guide-
lines for Dyslipidemias and Prevention of Atherosclerosis,
which consider total cholesterol ≥ 5.1 mmol/L and LDL-
c ≥ 4.1 mmol/L, were used [20, 21]. As for physical activity,
inactivity was considered for those who did not perform
any type of physical exercise on a regular basis for at least
3 times per week with at least 30 min. Smoking was
confirmed when the habit was present - regardless of
amount [21].
The patients were submitted to blood collection for
biochemical determination of diagnosis of PCOS at the
Centre for Clinical Research (CEPEC), University Hospital,
UFMA, in the morning between 7 to 9 h, after fasting for
12 h, in the follicular phase (third the seventh day of the
cycle) in those with regular menstrual cycles and any day
in those without regularity.
For each patient, 20 ml was collected whole blood and
stored under sterile vacuum tubes containing EDTA (for
blood count) and serology (separating gel) without anti-
coagulant for biochemical and hormonal evaluation, using
sterile equipment for such and disposable as the bio-
security standards for biological material.
The processing of blood samples was begun at most
1 h after collection. The serum samples were stored in a
freezer at −80 °C.
Fasting glucose and lipid profile were analyzed by
enzymatic colorimetric method. LDL-c was calculated
from the Friedewald formula: LDL-c = total cholesterol
(HDL-c – TG / 5), as there was in the samples, we
measured the upper TG 4.5 mmol/L. The biochemical
measurements were performed with the Cobas 6000
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The Shapiro-Wilk test was used to determine whether
the quantitative variables showed a normal distribution.
The frequency distribution (absolute and relative) was
performed for categorical variables. Quantitative CVD risk
variables are expressed as the mean and standard devi-
ation. A receiver operating characteristic (ROC) curve was
used to identify the LAP index as a predictor of CVD risk
as well as the cutoff point, estimating the highest sensitiv-
ity and specificity of this index. Logistic regression analysis
was used to evaluate the association between cardiovascu-
lar risk markers (BMI, fasting glucose, total cholesterol,
LDL-C, HDL-C, SBP, DBP, physical activity, and smoking
habits) and the LAP index. The adjusted logistic regres-
sion was used to further control potential bias. It is note-
worthy that there were no losses in the sample. The Stata®
12.0 program was used for statistical analysis and the
Microsoft Office 2010® software for data tabulation. A
level of significance of 5 % was adopted for all tests.
The study was approved by the Ethics Committee of
HU-UFMA (Permit No. 349/11) and all participants signed
a free informed consent form.per week with at least 30 minResults
The sociodemographic and behavioral characteristics of
the sample (n = 78). It is noteworthy that there was no
loss in the sample (all participants contemplated the in-
clusion criteria). Noted a high frequency of age group
18–26 years (50.0 %), unmarried (65.4 %), unpaid (51.3 %),
non-smokers (93.6 %) and physically active (79.5 %)
(Table 1).
Considering the trade-off between specificity and sen-
sitivity, the cut off point for the LAP index was ≥
37.9 cm.mmol/L (sensitivity: 85.19 %, specificity: 81.35 %),
corresponding to the value closer to 1.0 (best cutoff point),
Fig. 1.
All cardiovascular risk parameters were associated with
statistically the LAP index (p <0.05). Among women, 41 %
had changes in LAP. Among obese 17.7 % had changes in
the parameter, among those with high CC, 78.9 % among
those with hyperglycemia, 83.3 %. Regarding women with
lipid abnormalities, there was an association with changes
in LAP index by more than 60 % in all analyzed fractions,
Table 2.
Among the normotensive, SBP and DBP as, 82.9 %
was demonstrated-associated adjustments when the prod-
uct of lipid accumulation, Table 2.
All women with an LAP index above the defined cut off
point presented significantly more frequent altered mean
values of the cardiovascular risk markers analyzed. The
prevalence of women with an LAP index ≥ 37.9 cm.mmol/
L was 41 % (Table 3).The adjusted logistic regression was used to further
control pontenciais bias. The test showed that, except for
HDL-c, all cardiovascular risk markers presented a higher
chance of being altered when the LAP was above the
cutoff value of 37.9 cm.mmol/L. The other variables
significantly increased (p <0.05) the LAP at least 8.4 times
(CI > 1.0), except for HDL-c that was associated with a re-
duction in LAP (IC: 0.008 to 0.56), according to Table 4.
Were not included in the logistic regression model the
variables waist circumference and triglycerides by these
directly influence the value of the LAP.
The variables: BMI, fasting glucose, total cholesterol,
LDL-C, HDL-C, SBP, DBP, physical activity and smoking
habits were analyzed both in logistic regression models
unadjusted, as in adjusted.
Before of adjust, only BMI and HDL-C showed statisti-
cally significant association with the LAP index, after ad-
justment, BMI and DBP were associated with a higher risk
of changes in LAP and HDL-C to a reduction of changes
in marker.
Discussion
Cardiovascular risk parameters, were associated in women
with abnormal LAP index. By comparison, women with
such showed parameter higher measurements of BMI,
CC, fasting glucose, total coleterol, triglycerides, LDL-c,
SBP and DBP, as well as lower HDL-c.
Obesity marked by BMI and increased of DBP were as-
sociated with an increased risk of changes in LAP (above
Fig. 1 Distribution of lipid accumulation product (LAP index) values on the ROC curve of the sample. Lipid accumulation product
Table 2 Cardiovascular risk factors associated with changes in
LAP Index
Variable LAPa p –
value*≥37.9 cm.mmol/L <37.9 cm.mmol/L
(n = 32) (n = 46)
BMIb, n (%) <0.001
Not obese 23 (85.2) 4 (14.8)
Obese 9 (17.7) 42 (82.3)
WCc, n (%) <0.001
High 30 (78.9) 8 (21.1)
Normal 2 (5.0) 38 (95.0)
Fasting glucose, n (%) 0.028
High 5 (83.3) 1 (16.7)
Normal 27 (37.5) 45 (62.5)
Total cholesterol, n (%) 0.005
High 14 (66.7) 7 (33.3)
Normal 18 (31.6) 39 (68.4)
Triglycerides, n (%) <0.001
High 16 (94.1 1 (5.9)
Normal 16 (26.2) 45 (73.8)
LDL-cd, n (%) 0.005
High 11 (73.3) 4 (26.7)
Normal 21 (33.3) 42 (66.7)
HDL-ce, n (%) <0.001
Normal 20 (31.3) 44 (68.8)
Low 12 (85.7) 2 (14.3)
SBPf (mmHg) <0.001
Normotensive 6 (17.1) 29 (82.9)
Not normotensive 26 (60.5) 17 (39.5)
DBPg (mmHg) <0.001
Normotensive 7 (17.1) 34 (82.9)
Not normotensive 25 (67.6) 12 (32.4)
*Chi-square test; aLipid accumulation product (LAP index); bBody mass index;
cwaist circumference; dlow density lipoprotein; ehigh density lipoprotein;
fsystolic blood pressure; gdiastolic blood pressure
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vention for such change.
The aim of this study was to evaluate the association
between LAP index and cardiovascular risk factors in
women with PCOS. The results support the idea that
women with PCOS who have the LAP index above the
cut off suggested in this work showed the largest changes
in mean CVD risk markers analyzed.
Even with a small sample in a cross-sectional study,
considered a limitation in our study, the statistical ana-
lysis allowed away the null hypothesis. Still, some of the
highlights in the study are the making of laboratory tests
and the use of both anthropometric and blood pressure
direct measurement which shall not be obtained through
self-reference.
The adoption of low cost risk determining factors and
also with fast responses are of great help towards treat-
ment, tracking and early intervention which explains the
reason why such marker contributes to the early diagno-
sis of the main cause for women’s mortality in the world.
In this study, women with PCOS, concentrated in the
age group between 18 and 26 years, showing precocious-
ness in the accumulation of risk factors for CVD. Revealing
that this age group, an appropriate time for intervention in
the development of CVD. Physical inactivity is an import-
ant cardiovascular risk factor [22, 23]. The highest per-
centage of physical inactivity in this study may favour
the development of CVD especially when associated with
smoking [21]. However, this habit often in the sample was
low compared to the study of Junior Gil et al. [24].
The average age in our study was 26.3 years and the
BMI was 27.01 kg/m2 with LAP index cutoff rate at ≥
39.32 cm.mmol/L (81 % sensitivity and 82 % specificity)
on CVD risk with a prevalence of 38.5 %; yet Wiltgen et al.
[25] who evaluated LAP index in women with PCOS with
an age average of 20.6 years and BMI average of 29.5 kg/
m2 have come to a cut off rate of 37.87 cm.mmol/L (84 %
sensitivity and 79 % specificity) thus, higher rates than
Table 3 Distribution of cardiovascular risk markers according to
cut off value of the lipid accumulation product (LAP index)
Variable LAPa p
<37.9 cm.mmol/L ≥37.9 cm.mmol/L
BMIb (kg/m2) 23.1 ± 0.6 32.6 ± 0.9 <0.001
WCc (cm) 74.6 ± 1.3 98.9 ± 1.7 <0.001
Fasting glucose
(mmol/L)
4.7 ± 0.1 5.4 ± 0.3 0.006
Total cholesterol
(mmol/L)
4.4 ± 0.1 5.2 ± 0.2 <0.001
Triglycerides (mmol/L) 0.9 ± 0.0 2.0 ± 0.1 <0.001
LDL-cd (mmol/L) 2.6 ± 0.0 3.2 ± 0.1 <0.001
HDL-ce (mmol/L) 1.3 ± 0.0 1.0 ± 0.0 <0.001
SBPf (mmHg) 109.5 ± 1.7 122.8 ± 2.0 <0.001
DBPg (mmHg) 70.0 ± 1.2 80.0 ± 1.4 <0.001
Total, n (%) 46 (59) 32 (41)
Values are the mean ± standard deviation
aLipid accumulation product (LAP index); bbody mass index; cwaist
circumference; dlow density lipoprotein; ehigh density lipoprotein; fsystolic
blood pressure; gdiastolic blood pressure
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case was carried out where the whole PCOS group had
hyperandrogenism with high levels of testosterone. None-
theless, it is controversial that hyperandrogenism by itself
be considered a higher risk factor of CVD.
The combination of anovulation and hyperandrogen-
ism translates PCOS in its classical form which shows
the adverse metabolic phenotype of the syndrome. Such
phenotype includes visceral obesity and resistance to in-
sulin as well as a manifold of other traditional cardiovas-
cular risk factors especially inflammation, glucose and
dyslipidemia metabolism disorders [26].
The resulting risk increase of CVD may affect both
lean women and obese ones. The subjacent mechanisms
to the increase in cardiovascular risk within the PCOS
context may include not only metabolic alterations, but
also hormonal factors, hyperandrogenism in particular.
Nevertheless, the consequences in terms of cardiovascular
morbidity remain questionable due to the drawbacks in
carrying out long term prospective studies aiming at iden-
tifying potential factors from those clinical results [26].Table 4 Association between biases concerning cardiovascular
system risk indicators and biases in the lipid accumulation
product (LAP index) through adjusted logistic regression from
the female population with polycystic ovary syndrome
Altered Variables LAP1
Odds Confidence Interval Z P value
BMI2 ≥ 30 kg / m2 32.6 6.4 – 163.8 4.23 <0.0001
HDL-c3 1.2 mmol/L 0.06 0.008 – 0.56 −2.50 0.012
DBP4 ≥ 80 mmHg 8.4 1.86 – 37.9 2.77 0.006
1Lipid accumulation product (LAP index); 2body mass index; 3low density
lipoprotein; 4diastolic blood pressure.In this line of avaliation, 167 PCOS patients compared
to 102 controls were evaluated and such study aimed at
identifying coronary instability and diabetes mellitus type 2
through the frequency of CD4 (+) CD28 (null) lympho-
cytes that express the level of involvement by these
morbidities. It has been concluded that there is a posi-
tive association between the frequency of CD4 (+) CD28
(null) lymphocytes in PCOS patients when they are com-
pared to the control [27] showing that PCOS is a risk fac-
tor in the development of CVD.
For example it has been a study conducted with 139
women with PCOS aiming at evaluating both clinical and
endocrine pictures as well as cardiovascular disease risk
among the different PCOS phenotypes evaluated BMI
values, series levels of follicle-stimulating hormones (FSH),
luteinizing hormone (LH), progesterone, estradiol, testos-
terone, dehydroepiandrosteronesulphate (S-DHEA), fasting
glucose, low density lipoprotein (LDL-C), total cholesterol,
high density lipoprotein (HDL-C), C-reative protein, insu-
lin, sensitivity to insulin and thickness of the carotid inner
layer has found that the hyperandrogenic phenotype has
lower risk of cardiovascular disease in comparison to other
phenotypes [28].
Taking into account that the risk of cardiometabolic
disorders may be partly determined by the employed def-
inition of PCOS, clinical and epidemiological studies sup-
port the need to identify women with PCOS to determine
the risk of cardiometabolic diseases and thus prevent
and/or treat its serious consequences [29].
Women with PCOS associated with the presence of
obesity, smoking habits, dyslipidemia, high blood pressure,
intolerance to glucose and subclinical vascular disease are
at risk whereas those with metabolic syndrome and/or dia-
betes mellitus type 2 pose high risk of CVD. It is therefore
recommended that those women manage their lifestyles in
order to seek the primary prevention of CVD [30].
Following the above findings with different design, pro-
spective study, conducted at the Endocrinology, Diabetes
and Metabolic Diseases Clinic at the University Center of
Sarajevo, 50 patients diagnosed with PCOS in accordance
with the Rotterdam criteria – ESHRE [5] were divided into
two groups according to their BMI and had the following
parameters evaluated: anthropometric indices (WC, height
and weight), BMI, TG, resistance to insulin and the LAP
index. Results showed that women with PCOS and BMI ≤
24.9 kg/m2 were significantly different from those with
BMI > 25 kg/m2 in body weight, WC and TG. Besides the
LAP index having been a marker to differentiate women
who were resistant to insulin from those who were not
with a cut off value of 17.91 cm.mmol/L, the women
group with BMI > 25 kg/m2 showed higher values of
the LAP index. We may conclude that the LAP index is
a marker to differentiate resistance to insulin in women
with PCOS [31].
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ance to insulin in women with PCOS is significantly
higher when compared to the population in general mak-
ing the LAP index a new, cheap and accessible predictor
of the metabolic syndrome both to the general population
and women with PCOS [31].
In relation the area found under curve ROC (0.8845)
shows that the LAP index presents satisfactory perform-
ance in those circumstances as its area above 0.70 trans-
lates a test with adequate diagnosis [32].
When screening patients under risk to develop CVD it
is important that diagnostic tests present optimum sensi-
tivity to detect disease or alterations in apparently healthy
people (asymptomatic patients) [33]. Different studies
indicated that the LAP index may be used as a screening
marker when identifying patients who are likely to be
characterized with the atherogenic metabolic triad: fasting
hyperinsulinemia, hyperapolipo protein B and high pro-
portion of small LDL-c particles [15, 16, 25, 34]. Notwith-
standing, the LAP index discriminatory reach to identify
patients with cardiometabolic risk profile may be com-
pared to those of IDF and National Cholesterol Education
Program – Adult Treatment Panel III (NCEP-ATP III)
[20, 35] as it shows sensitivity, specificity [25] and low cost
to identify people under higher cardiovascular risk.
Indeed, it is important to determine such index to evalu-
ate women with PCOS once BMI alone is not capable of
marking the fat deposition characteristic in the body [15].
It is doubtless that women with PCOS show high preva-
lence of central obesity [36, 37]. Studies demonstrate that
50 to 60 % of those patients present abdominal obesity re-
gardless of their BMI [36–39].
Clinical practice and literature data have shown a high
prevalence of cardiovascular risk indicators in women
with PCOS [36, 37]. Since obesity is an independent risk
factor of CVD [39], in our study the prevalence of obes-
ity was 34.6 % with PCOS and its control is fundamental
to improve clinical and biochemical alterations [13, 38].
Another variable used was WC, which is an indicator of
abdominal adiposity and is widely used as a predictor of
cardiovascular risk [39]. The frequency of increased WC
was 41 %, a finding indicating its association with this
syndrome [37].
Another risk factor for CVD already established is
HDL-c levels below the recommended limit, irrespective
of LDL-c values [10]. The percentage of women with re-
duced HDL-c observed in the present study was higher
than that reported by Apridonidze et al. [40] who de-
tected low HDL-c levels in 49 % of women with PCOS.
A recent study including 406 patients with PCOS and
342 control women aged between 17 and 40 within a
certain population in Southeast Asia between 2006 and
2011, a prevalence of 52.96 % of PCOS patients with
dyslipidemia was found, which was around twice as muchas in the controls, 28.95 %. The most common dyslipid-
emia components in PCOS patients were lowered levels of
HDL-c (41.13 %) and an increase in TG (24.14 %). The
frequency of metabolic syndrome in PCOS patients was
25.62 % which is more than five times higher when
compared to the controls. The two main risk factors were
the increase in waist circumference and low levels of
HDL-c [41].
Obese women with PCOS present high SBP and DBP,
suggesting that arterial hypertension is a late sequel of
the stimulatory effects of hyperinsulinemia on the sym-
pathetic nervous system and vascular smooth muscle
[42]. In our study, the frequency of women with altered
SBP and DBP was 14.1 %. In a case–control results with
60 women aged between 18 and 45 where 42 women
with PCOS and 18 controls, observed no differences be-
tween the metabolic parameters and resistance to insulin
in both groups. Comparing those parameters (metabolic
and resistance to insulin) with 24-h blood pressure mon-
itoring in the ambulatory (MAPA) it was shown that the
only correlating parameter was the BMI, regardless of
PCOS diagnosis. Such study observed that PCOS women
did not show higher levels of blood pressure, glycemia,
HDL-c, TG, resistance to insulin and BMI in comparison
to the control group. However, women presented correl-
ation among PCOS, blood pressure and BMI, suggesting
that obesity is a main factor involved in blood pressure
changes in those women [43].
Therefore, the use of anthropometric indices for the
diagnostic evaluation of central obesity seems to be more
adequate in this subgroup of women [13]. Using the cut
off identified here, the LAP index may be a more access-
ible and more accurate tool to identify cardiovascular risk
in women with PCOS and can be adopted and included in
clinical practice by SUS on a regular basis since it is easy
to be obtained and represents lower screening costs con-
cerning those women under metabolic risk.Competing interest
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